Cymabay Therapeutics Inc expected to post a loss of 24  cents a share - Earnings Preview

CymaBay Therapeutics

11/05/2021 21:03

* Cymabay Therapeutics Inc  CBAY.OQ   CBAY.O  is expected
to show a no change in quarterly revenue when it reports
results on May 13 .
​* Refinitiv's mean analyst estimate for Cymabay Therapeutics
Inc is for a loss of 24 cents per share. For the same quarter
last year, the company reported a loss of 19 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had fallen by
about 0.6% in the last three months. ​
* Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $12​, about 67.2% above​ its last closing
price of $3.94. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020              -0.20      -0.23     Missed  -14.9
 Sep. 30 2020  -0.17       -0.17      -0.17     Met     -2.4
 Jun. 30 2020  -0.23       -0.24      -0.16     Beat    33.1​
 Mar. 31 2020  -0.30       -0.30      -0.19     Beat    36.5
 Dec.          -0.37​      -0.39      -0.35     Beat    10​
 31​ 2019​                                              
 Sep. 30 2019  -0.38       -0.37      -0.38     Missed  -3.1​
 Jun. 30 2019  -0.36       -0.37      -0.35     Beat    4.5
 Mar. 31 2019  -0.34       -0.34      -0.37     Missed  -9.5
 This summary was machine generated May 11 at 20:03 GMT.  All
figures in US dollars unless otherwise stated